CAPItello-292 Phase 3: an Open-Label, Randomized Study of Capivasertib, Fulvestrant, and Investigator's Choice of CDK4/6 Inhibitor (palbociclib or Ribociclib) in HR+/HER2-advanced Breast Cancer
CANCER RESEARCH（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined